Literature DB >> 21654344

Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.

Kerrington R Molhoek1, Amber L Shada, Mark Smolkin, Sudhir Chowbina, Jason Papin, David L Brautigan, Craig L Slingluff.   

Abstract

Melanomas depend on autocrine signals for proliferation and survival; however, no systematic screen of known receptor tyrosine kinases (RTKs) has been performed to identify which autocrine signaling pathways are activated in melanoma. Here, we performed a comprehensive analysis of 42 RTKs in six individual human melanoma tumor specimens as well as 17 melanoma cell lines, some of which were derived from the tumor specimens. We identified five RTKs that were active in almost every one of the melanoma tissue specimens and cell lines, including two previously unreported receptors, insulin-like growth factor receptor 1 (IGF-1R) and macrophage-stimulating protein receptor (MSPR), in addition to three receptors (vascular endothelial growth factor receptor, fibroblast growth factor receptor, and hepatocyte growth factor receptor) known to be autocrine activated in melanoma. We show, by quantitative real time PCR, that all melanoma cell lines expressed genes for the RTK ligands such as HGF, IGF-1, and MSP. Addition of antibodies to either IGF-1 or HGF, but not to MSP, to the culture medium blocked melanoma cell proliferation, and even caused net loss of melanoma cells. Antibody addition deactivated IGF-1R and hepatocyte growth factor receptors, as well as mitogen-activated protein kinase signaling. Thus, IGF-1 is a new growth factor for autocrine driven proliferation of human melanoma in vitro. Our results suggest that IGF-1-IGF-1R autocrine pathway in melanoma is a possible target for therapy in human melanomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21654344      PMCID: PMC3131461          DOI: 10.1097/CMR.0b013e328343a1d6

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  53 in total

1.  The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.

Authors:  T L Darrow; C L Slingluff; H F Seigler
Journal:  J Immunol       Date:  1989-05-01       Impact factor: 5.422

Review 2.  Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review).

Authors:  T Moriyama; H Kataoka; M Koono; S Wakisaka
Journal:  Int J Mol Med       Date:  1999-05       Impact factor: 4.101

3.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

Review 4.  RON, a tyrosine kinase receptor involved in tumor progression and metastasis.

Authors:  E Ramsay Camp; Wenbiao Liu; Fan Fan; Anthony Yang; Ray Somcio; Lee M Ellis
Journal:  Ann Surg Oncol       Date:  2005-03-15       Impact factor: 5.344

5.  Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF).

Authors:  M J Hendrix; E A Seftor; R E Seftor; D A Kirschmann; L M Gardner; H C Boldt; M Meyer; J Pe'er; R Folberg
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

Review 6.  Met-HGF/SF: tumorigenesis, invasion and metastasis.

Authors:  G F Vande Woude; M Jeffers; J Cortner; G Alvord; I Tsarfaty; J Resau
Journal:  Ciba Found Symp       Date:  1997

7.  Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells.

Authors:  R Halaban; J S Rubin; Y Funasaka; M Cobb; T Boulton; D Faletto; E Rosen; A Chan; K Yoko; W White
Journal:  Oncogene       Date:  1992-11       Impact factor: 9.867

Review 8.  Role of growth factors and their receptors in the development and progression of melanoma.

Authors:  I M Shih; M Herlyn
Journal:  J Invest Dermatol       Date:  1993-02       Impact factor: 8.551

9.  KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.

Authors:  Harri Sihto; Maarit Sarlomo-Rikala; Olli Tynninen; Minna Tanner; Leif C Andersson; Kaarle Franssila; Nina N Nupponen; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

10.  Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin.

Authors:  Kerrington R Molhoek; David L Brautigan; Craig L Slingluff
Journal:  J Transl Med       Date:  2005-10-28       Impact factor: 5.531

View more
  21 in total

1.  Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.

Authors:  Yibing Ruan; Anna Kovalchuk; Aarthi Jayanthan; Xueqing Lun; Yoji Nagashima; Olga Kovalchuk; James R Wright; Alfredo Pinto; Adam Kirton; Ronald Anderson; Aru Narendran
Journal:  Neuro Oncol       Date:  2014-11-12       Impact factor: 12.300

2.  Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.

Authors:  Inna V Fedorenko; Bin Fang; John M Koomen; Geoffrey T Gibney; Keiran S M Smalley
Journal:  Melanoma Res       Date:  2014-10       Impact factor: 3.599

3.  Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).

Authors:  Craig L Slingluff; Gina R Petroni; Kerrington R Molhoek; David L Brautigan; Kimberly A Chianese-Bullock; Amber L Shada; Mark E Smolkin; Walter C Olson; Alison Gaucher; Cheryl Murphy Chase; William W Grosh; Geoffrey R Weiss; Aubrey G Wagenseller; Anthony J Olszanski; Lainie Martin; Sofia M Shea; Gulsun Erdag; Prahlad Ram; Jeffrey E Gershenwald; Michael J Weber
Journal:  Clin Cancer Res       Date:  2013-04-25       Impact factor: 12.531

4.  Inhibition of human breast cancer Matrigel invasion by Streptolysin O activation of the EGF receptor ErbB1.

Authors:  Emily H Hall; Volkan Gurel; Albert E Dahlberg; John McMichael; David L Brautigan
Journal:  Cell Signal       Date:  2011-07-20       Impact factor: 4.315

Review 5.  NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.

Authors:  I V Fedorenko; G T Gibney; K S M Smalley
Journal:  Oncogene       Date:  2012-10-15       Impact factor: 9.867

6.  Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.

Authors:  Devin G Roller; Mark Axelrod; Brian J Capaldo; Karin Jensen; Aaron Mackey; Michael J Weber; Daniel Gioeli
Journal:  Mol Cancer Ther       Date:  2012-09-07       Impact factor: 6.261

Review 7.  Ron receptor tyrosine kinase signaling as a therapeutic target.

Authors:  Nancy M Benight; Susan E Waltz
Journal:  Expert Opin Ther Targets       Date:  2012-07-26       Impact factor: 6.902

8.  Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor.

Authors:  Jessica L F Teh; Raj Shah; Seung-Shick Shin; Yu Wen; Janice M Mehnert; James Goydos; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2014-04-11       Impact factor: 4.693

9.  Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor.

Authors:  Liron Zehavi; Roi Avraham; Aviv Barzilai; Dalia Bar-Ilan; Roy Navon; Yechezkel Sidi; Dror Avni; Raya Leibowitz-Amit
Journal:  Mol Cancer       Date:  2012-07-02       Impact factor: 27.401

Review 10.  Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches.

Authors:  Punit Saraon; Shivanthy Pathmanathan; Jamie Snider; Anna Lyakisheva; Victoria Wong; Igor Stagljar
Journal:  Oncogene       Date:  2021-06-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.